We are live on
!
Find out more
GGI
GordonMD Global Investments Portfolio holdings
AUM
$207M
This Fund
S&P 500
This Quarter
Est. Return
+29.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$207M
AUM Growth
+$63.1M
(+44%)
Cap. Flow
+$65.9M
Cap. Flow
% of AUM
31.91%
Top 10 Holdings %
Top 10 Hldgs %
83.89%
Holding
17
New
1
Increased
4
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$38.1M |
| 2 |
Pyxis Oncology
PYXS
|
+$11.3M |
| 3 |
Editas Medicine
EDIT
|
+$9.14M |
| 4 |
Allogene Therapeutics
ALLO
|
+$8.49M |
| 5 |
Celldex Therapeutics
CLDX
|
+$3.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tarsus Pharmaceuticals
TARS
|
+$2.99M |
| 2 |
Vir Biotechnology
VIR
|
+$1.57M |
| 3 |
Taysha Gene Therapies
TSHA
|
+$85K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kyverna Therapeutics
KYTX
$547M
| $37.8M | 18.3% |
4,244,818
| – | – |
|
|
2
Pyxis Oncology
PYXS
$254M
| $30.2M | 14.6% |
10,024,909
+5,903,039
| +143% | +$11.3M |
|
|
3
Taysha Gene Therapies
TSHA
$2.02B
| $24.5M | 11.86% |
723,185
-14,365
| -2% | -$85K |
|
|
4
Teva Pharmaceuticals
TEVA
$44.4B
| $16.4M | 7.92% |
2,402,495
+1,145,000
| +91% | +$38.1M |
|
|
5
Vir Biotechnology
VIR
$1.81B
| $13.8M | 6.67% |
1,353,552
-165,000
| -11% | -$1.57M |
|
|
6
Allogene Therapeutics
ALLO
$750M
| $11M | 5.33% |
5,298,000
+3,868,000
| +270% | +$8.49M |
|
|
7
Celldex Therapeutics
CLDX
$3.24B
| $10.4M | 5.04% |
279,720
+109,413
| +64% | +$3.53M |
|
|
8
Editas Medicine
EDIT
$505M
| $10.1M | 4.9% |
+3,127,000
| New | +$9.14M |
|
9
Ultragenyx Pharmaceutical
RARE
$2.61B
| $9.65M | 4.67% |
289,101
| – | – |
|
10
Bausch + Lomb
BLCO
$6.16B
| $9.5M | 4.6% |
573,472
| – | – |
|
11
Amgen
AMGN
$239B
| $7.32M | 3.54% |
20,212
| – | – |
|
12
Scholar Rock
SRRK
$7.09B
| $7.29M | 3.53% |
132,500
| – | – |
|
|
SION
13
Sionna Therapeutics
SION
$283M
| $5.98M | 2.89% |
136,000
| – | – |
|
14
Incyte
INCY
$26.3B
| $4.91M | 2.38% |
43,300
| – | – |
|
15
Crinetics Pharmaceuticals
CRNX
$9B
| $4.75M | 2.3% |
126,985
| – | – |
|
16
Insmed
INSM
$27B
| $3.05M | 1.47% |
28,587
| – | – |
|
|
17
Tarsus Pharmaceuticals
TARS
$3.13B
| – | – |
-42,680
| Closed | -$2.99M |
|
Similar funds
AWS
OPF
AWP
MKW
SPI
AP
HI
HA
GordonMD Global Investments's Q2 2026 Portfolio in Review
As of Q2 2026, GordonMD Global Investments held 17 positions worth $207M, up 44% from $144M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
GordonMD Global Investments deployed $65.9M of net new capital in Q2 2026, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Editas Medicine: 3,127,000 shares worth $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Vir Biotechnology, an estimated $1.57M trimmed.
- GordonMD Global Investments's largest Q2 2026 buy was Editas Medicine: 3,127,000 shares worth $10.1M.
- GordonMD Global Investments added most to Teva Pharmaceuticals in Q2 2026, an estimated $38.1M increase.
- GordonMD Global Investments's biggest Q2 2026 reduction was Vir Biotechnology, cutting an estimated $1.57M.
- GordonMD Global Investments fully exited Tarsus Pharmaceuticals in Q2 2026, selling an estimated $2.99M.
- GordonMD Global Investments's ten largest holdings make up 84% of its $207M portfolio in Q2 2026.
- GordonMD Global Investments opened 1 new position and closed 1 in Q2 2026.
- GordonMD Global Investments's portfolio value rose 44% quarter-over-quarter to $207M.
Based on GordonMD Global Investments's 13F filing for Q2 2026, filed 14 Aug 2026.